Molecular and Cellular Biochemistry

, Volume 296, Issue 1–2, pp 85–95 | Cite as

Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin

  • Pornngarm LimtrakulEmail author
  • Wanida Chearwae
  • Suneet Shukla
  • Chada Phisalphong
  • Suresh V. Ambudkar
Original Paper


Many studies have been performed with the aim of developing effective resistance modulators to overcome the multidrug resistance (MDR) of human cancers. Potent MDR modulators are being investigated in clinical trials. Many current studies are focused on dietary herbs due to the fact that these have been used for centuries without producing any harmful side effects. In this study, the effect of tetrahydrocurcumin (THC) on three ABC drug transporter proteins, P-glycoprotein (P-gp or ABCB1), mitoxantrone resistance protein (MXR or ABCG2) and multidrug resistance protein 1 (MRP1 or ABCC1) was investigated, to assess whether an ultimate metabolite form of curcuminoids (THC) is able to modulate MDR in cancer cells. Two different types of cell lines were used for P-gp study, human cervical carcinoma KB-3-1 (wild type) and KB-V-1 and human breast cancer MCF-7 (wild type) and MCF-7 MDR, whereas, pcDNA3.1 and pcDNA3.1-MRP1 transfected HEK 293 and MXR overexpressing MCF7AdrVp3000 or MCF7FL1000 and its parental MCF-7 were used for MRP1 and MXR study, respectively. We report here for the first time that THC is able to inhibit the function of P-gp, MXR and MRP1. The results of flow cytometry assay indicated that THC is able to inhibit the function of P-gp and thereby significantly increase the accumulation of rhodamine and calcein AM in KB-V-1 cells. The result was confirmed by the effect of THC on [3H]-vinblastine accumulation and efflux in MCF-7 and MCF-7MDR. THC significantly increased the accumulation and inhibited the efflux of [3H]-vinblastine in MCF-7 MDR in a concentration-dependent manner. This effect was not found in wild type MCF-7 cell line. The interaction of THC with the P-gp molecule was clearly indicated by ATPase assay and photoaffinity labeling of P-gp with transport substrate. THC stimulated P-gp ATPase activity and inhibited the incorporation of [125I]-iodoarylazidoprazosin (IAAP) into P-gp in a concentration-dependent manner. The binding of [125I]-IAAP to MXR was also inhibited by THC suggesting that THC interacted with drug binding site of the transporter. THC dose dependently inhibited the efflux of mitoxantrone and pheophorbide A from MXR expressing cells (MCF7AdrVp3000 and MCF7FL1000). Similarly with MRP1, the efflux of a fluorescent substrate calcein AM was inhibited effectively by THC thereby the accumulation of calcein was increased in MRP1-HEK 293 and not its parental pcDNA3.1-HEK 293 cells. The MDR reversing properties of THC on P-gp, MRP1, and MXR were determined by MTT assay. THC significantly increased the sensitivity of vinblastine, mitoxantrone and etoposide in drug resistance KB-V-1, MCF7AdrVp3000 and MRP1-HEK 293 cells, respectively. This effect was not found in respective drug sensitive parental cell lines. Taken together, this study clearly showed that THC inhibits the efflux function of P-gp, MXR and MRP1 and it is able to extend the MDR reversing activity of curcuminoids in vivo.


ABC transporter ATP hydrolysis chemosensitivity drug transport multidrug resistance P-glycoprotein tetrahydrocurcumin 



ATP-binding cassette




multidrug resistance protein 1


mitoxantrone resistance protein






Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



This work was supported by Grants from the Thailand National Center for Genetic Engineering and Biotechnology (BIOTEC), the National Science and Technology Development Agency (NSTDA) and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.


  1. 1.
    Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1991) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361–398CrossRefGoogle Scholar
  2. 2.
    Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48–58PubMedCrossRefGoogle Scholar
  3. 3.
    Lage H (2003) ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22: 188–199PubMedCrossRefGoogle Scholar
  4. 4.
    Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67–113PubMedCrossRefGoogle Scholar
  5. 5.
    Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV (2001) The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 33: 481–491PubMedCrossRefGoogle Scholar
  6. 6.
    Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931–959PubMedCrossRefGoogle Scholar
  7. 7.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972PubMedGoogle Scholar
  8. 8.
    Twentyman PR, Bleehen NM (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 7: 1639–1642Google Scholar
  9. 9.
    Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O (2000) Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6: 4416–4421PubMedGoogle Scholar
  10. 10.
    Green LJ, Marder P, Slapak CA (2001) Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 61: 1393–1399PubMedCrossRefGoogle Scholar
  11. 11.
    Pan MH, Huang TM, Lin JK (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27: 486–494PubMedGoogle Scholar
  12. 12.
    Lin JK, Lin-Shiau SY (2001) Mechanisms of cancer chemoprevention by curcumin. Proc Natl Sci Counc Repub China B 25: 59–66PubMedGoogle Scholar
  13. 13.
    Lin JK, Pan MH Lin-Shiau SY (2000) Recent studies on the biofunctions and biotransformations of curcumin Biofactors 13: 153–158PubMedGoogle Scholar
  14. 14.
    Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, Gescher AJ (2002) Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11: 105–111PubMedGoogle Scholar
  15. 15.
    Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363–398PubMedGoogle Scholar
  16. 16.
    Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61: 1058–1064PubMedGoogle Scholar
  17. 17.
    Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P (2004) Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 68: 2043–2052PubMedCrossRefGoogle Scholar
  18. 18.
    Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV, Limtrakul P (2005) Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol 57: 376–388PubMedCrossRefGoogle Scholar
  19. 19.
    Cheawae W, Shukla S, Limtrakul P, Ambudkar SV: Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther 5: 1995–2006, 2006Google Scholar
  20. 20.
    Venkateswarlu S, Rambabu M, Subbaraju GV (2001) Synthesis of gingerone-A and hirsutenone. Indian J Chem 40: 495–497Google Scholar
  21. 21.
    Sugiyama Y, Kawakishi S, Osawa T (1996) Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem Pharmacol 52: 519–525PubMedCrossRefGoogle Scholar
  22. 22.
    Clark R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM, Dickson R (1992) Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 84: 1506–1512CrossRefGoogle Scholar
  23. 23.
    Muller M, Yong M, Peng XH, Petre B, Arora S, Ambudkar SV (2002) Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry 41: 10123–10132PubMedCrossRefGoogle Scholar
  24. 24.
    Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7: 145–152PubMedGoogle Scholar
  25. 25.
    Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, Bates SE (2001) A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512: 171–182PubMedCrossRefGoogle Scholar
  26. 26.
    Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61: 6635–6639PubMedGoogle Scholar
  27. 27.
    Plouzek CA, Ciolino HP, Clarke R, Yeh GC (1999) Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur J Cancer 35: 1541–1545PubMedCrossRefGoogle Scholar
  28. 28.
    Jodoin J, Demeule M, Beliveau R (2002) Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542: 149–159PubMedCrossRefGoogle Scholar
  29. 29.
    Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM Pastan I (1998) Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37: 5010–5019PubMedCrossRefGoogle Scholar
  30. 30.
    Sauna ZE, Ambudkar SV (2001) Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J Biol Chem 276: 11653–11661PubMedCrossRefGoogle Scholar
  31. 31.
    Sauna ZE, Nandigama K, Ambudkar SV (2004) Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. J Biol Chem 279: 48855–48864PubMedCrossRefGoogle Scholar
  32. 32.
    Sauna ZE, Smith MM, Muller M, Ambudkar SV (2001) Functionally similar vanadate-induced 8-azidoadenosine 5′-[alpha-(32)P]Diphosphate-trapped transition state intermediates of human P-glycoprotin are generated in the absence and presence of ATP hydrolysis. J Biol Chem 276: 21199–21208PubMedCrossRefGoogle Scholar
  33. 33.
    Ambudkar SV (1998) Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol 292: 504–514PubMedCrossRefGoogle Scholar
  34. 34.
    Greenberger LM, Yang CP, Gindin E, Horwitz SB (1990) Photoaffinity probes for the alpha 1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J Biol Chem 265: 4394–4401PubMedGoogle Scholar
  35. 35.
    Hrycyna CA, Ramachandra M, Ambudkar SV, Ko YH, Pedersen PL, Pastan I, Gottesman MM (1998) Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites. J Biol Chem 273: 16631–16634PubMedCrossRefGoogle Scholar
  36. 36.
    Ejendal KF, Hrycyna CA (2005) Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol Pharmacol 67: 902–911PubMedCrossRefGoogle Scholar
  37. 37.
    Araujo CC, Leon LL (2001) Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 96: 723–728PubMedCrossRefGoogle Scholar
  38. 38.
    Miquel J, Bernd A, Sempere JM, Diaz-Alperi J, Ramirez A (2002) The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr 34: 37–46PubMedCrossRefGoogle Scholar
  39. 39.
    Nakamura Y, Ohto Y, Murakami A, Osawa T, Ohigashi H (1998) Inhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor promoter-induced reactive oxygen species generation in leukocytes in vitro and in vivo. Jpn J Cancer Res 89: 361–370PubMedGoogle Scholar
  40. 40.
    Osawa T, Kato Y (2005) Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann NY Acad Sci 1043: 440–451PubMedCrossRefGoogle Scholar
  41. 41.
    Atsumi T, Fujisawa S, Tonosaki K (2005) Relationship between intracellular ROS production and membrane mobility in curcumin- and tetrahydrocurcumin-treated human gingival fibroblasts and human submandibular gland carcinoma cells. Oral Dis 11: 236–242PubMedCrossRefGoogle Scholar
  42. 42.
    Pari L, Amali DR (2005) Protective role of tetrahydrocurcumin (THC) an active principle of turmeric on chloroquine induced hepatotoxicity in rats. J Pharm Pharm Sci 8: 115–123PubMedGoogle Scholar
  43. 43.
    Girija CR, Begum NS, Syed AA, Thiruvenkatam V (2004) Hydrogen-bonding and C–H pi interactions in 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione (tetrahydrocurcumin). Acta Crystallogr C 60: 611–613CrossRefGoogle Scholar
  44. 44.
    Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM, Dickson RB (1992) Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 84: 1506–1512PubMedCrossRefGoogle Scholar
  45. 45.
    Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS (2003) Involvement of multidrug resistance-associated proteins in regulating cellular levels of (−)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun 310: 222–227PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Pornngarm Limtrakul
    • 1
    • 4
    Email author
  • Wanida Chearwae
    • 1
    • 2
  • Suneet Shukla
    • 2
  • Chada Phisalphong
    • 3
  • Suresh V. Ambudkar
    • 2
  1. 1.Department of Biochemistry, Faculty of MedicineChiang Mai UniversityChiang MaiThailand
  2. 2.Laboratory of Cell Biology, Center for Cancer ResearchNational Cancer Institute, NIH, DHHSBethesdaUSA
  3. 3.Research and Development InstituteGovernment Pharmaceutical Organization BangkokThailand
  4. 4.Department of Biochemistry, Faculty of MedicineChiang Mai UniversityChiang MaiThailand

Personalised recommendations